{"filing":{"accession_number":"0001104659-26-082116","cik":"0001638287","ticker":"MTVA","company_name":"MetaVia Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"tm2620006d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/tm2620006d1_8k.htm"},"events":[{"id":17194,"run_id":15382,"accession_number":"0001104659-26-082116","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MetaVia announced completion of dose titration in its Phase 1 Part 3 clinical trial for DA-1726, with all enrolled patients successfully reaching their highest target doses of 48 mg and 64 mg. Topline data is expected in Q4 2026, representing a material clinical development milestone for the clinical-stage biotech company.","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15557,"accession_number":"0001104659-26-082116","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia announced completion of dose titration in its Phase 1 Part 3 clinical trial for DA-1726, with all enrolled patients reaching their highest target doses and topline data expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the specific event categories (earnings, executive changes, M\u0026A, impairment, etc.). It is clearly operational/strategic in nature—a significant progress update on the company's lead drug candidate—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:02:41.152284+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15558,"accession_number":"0001104659-26-082116","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia disclosed completion of dose titration in Part 3 of its Phase 1 clinical trial for DA-1726, with all enrolled patients successfully reaching target doses of 48 mg and 64 mg. This represents a material clinical development milestone for a clinical-stage biotech company, as it demonstrates progress toward the planned Q4 2026 data readout. While this is an operational/clinical event rather than a financial, governance, or legal matter, it is material to investors assessing the company's pipeline advancement and de-risking of its lead program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:02:41.152284+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15557,"accession_number":"0001104659-26-082116","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia announced completion of dose titration in its Phase 1 Part 3 clinical trial for DA-1726, with all enrolled patients reaching their highest target doses and topline data expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the specific event categories (earnings, executive changes, M\u0026A, impairment, etc.). It is clearly operational/strategic in nature—a significant progress update on the company's lead drug candidate—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:02:41.152284+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-07-09"},{"id":15558,"accession_number":"0001104659-26-082116","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia disclosed completion of dose titration in Part 3 of its Phase 1 clinical trial for DA-1726, with all enrolled patients successfully reaching target doses of 48 mg and 64 mg. This represents a material clinical development milestone for a clinical-stage biotech company, as it demonstrates progress toward the planned Q4 2026 data readout. While this is an operational/clinical event rather than a financial, governance, or legal matter, it is material to investors assessing the company's pipeline advancement and de-risking of its lead program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:02:41.152284+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-07-09"}]}